STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNSE
  4. [Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity

Sensei Biotherapeutics (SNSE) president awarded 220,000 stock options at $29.89

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Sensei Biotherapeutics, Inc. reported that its President & PEO, Gerry Christopher, received a grant of stock options covering 220,000 shares of common stock. The options have an exercise price of $29.89 per share and were approved under the company’s 2026 Equity Incentive Plan after stockholder approval.

According to the vesting terms, 25% of the option vests and becomes exercisable on April 10, 2027, with the remaining shares vesting in 36 equal monthly installments so that the award is fully vested by April 10, 2030, contingent on his continued service with the company.

Positive

  • None.

Negative

  • None.
Insider Gerry Christopher
Role President & PEO
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 220,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 220,000 shares (Direct, null)
Footnotes (1)
  1. The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026. 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Stock options granted 220,000 options Grant to President & PEO Gerry Christopher
Exercise price $29.89 per share Closing price on April 10, 2026
Shares underlying options 220,000 shares Common stock underlying the option
Initial vesting date April 10, 2027 25% of options vest
Full vesting date April 10, 2030 Options fully vested by fourth anniversary
Option expiration June 9, 2036 Expiration date of the option
Plan approval date June 10, 2026 Stockholders approved 2026 Equity Incentive Plan
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
2026 Equity Incentive Plan financial
"subject to stockholder approval of the 2026 Equity Incentive Plan"
exercise price financial
"The exercise price reflects the closing price of the Issuer's common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the shares subject to the option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service with the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gerry Christopher
(Last)(First)(Middle)
C/O SENSEI BIOTHERAPEUTICS, INC.
1405 RESEARCH BLVD, SUITE 125
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President & PEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$29.8906/10/2026(1)A220,000 (2)06/09/2036Common Stock220,000$0220,000D
Explanation of Responses:
1. The stock option grant was approved by the Issuer's Board of Directors on April 10, 2026, subject to stockholder approval of the 2026 Equity Incentive Plan, which approval was obtained on June 10, 2026. The exercise price reflects the closing price of the Issuer's common stock on April 10, 2026.
2. 25% of the shares subject to the option vest and become exercisable on April 10, 2027, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter, such that the option is fully vested on the fourth anniversary of the vesting commencement date, or April 10, 2030, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
/s/ Christopher Gerry06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Sensei Biotherapeutics (SNSE) disclose in this Form 4?

Sensei Biotherapeutics disclosed that President & PEO Gerry Christopher received a stock option grant for 220,000 shares. The award is part of his compensation and gives him the right to buy common stock at a fixed exercise price if vesting conditions are met.

How many Sensei Biotherapeutics (SNSE) stock options were granted to Gerry Christopher?

Gerry Christopher was granted stock options covering 220,000 shares of Sensei Biotherapeutics common stock. These options represent a right to acquire shares in the future, subject to vesting over time and payment of the specified exercise price per share.

What is the exercise price of the new SNSE stock options?

The stock options granted to Gerry Christopher have an exercise price of $29.89 per share. This price equals the closing price of Sensei Biotherapeutics common stock on April 10, 2026, the date the Board approved the option grant under the 2026 Equity Incentive Plan.

How do the SNSE stock options for Gerry Christopher vest over time?

The options vest with 25% becoming exercisable on April 10, 2027, and the remaining shares vesting in 36 equal monthly installments. The award becomes fully vested by April 10, 2030, provided Gerry Christopher remains in continuous service with Sensei Biotherapeutics.

Was shareholder approval required for the SNSE option grant to Gerry Christopher?

Yes. The stock option grant was approved by the Board on April 10, 2026, but was subject to stockholder approval of the 2026 Equity Incentive Plan. That stockholder approval was obtained on June 10, 2026, allowing the grant terms to take effect as described.

What role does Gerry Christopher hold at Sensei Biotherapeutics (SNSE)?

Gerry Christopher serves as President & Principal Executive Officer of Sensei Biotherapeutics. The reported Form 4 reflects a stock option grant he received in this executive capacity, aligning his potential future equity ownership with the company’s long-term performance.